Clinical Trial Detail

NCT ID NCT01822652
Title 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Baylor College of Medicine
Indications

neuroblastoma

Therapies

Cyclophosphamide

Fludarabine

Pembrolizumab

Age Groups: child adult

No variant requirements are available.